Asia shares trade mixed on Thursday, as tech shares stabilized from their recent losses. Australian markets hit record highs, driven by strong business activity data for August. On the geopolitical front,

President Trump has focused on Ukraine and Russia in recent days, but other developments are quietly moving ahead in another part of the world: China. HPR's Bill Dorman has more in today's Asia Minute.

The success or failure of China's security initiatives in Southeast Asia depends on the domestic politics of Southeast Asian states and the Chinese leadership's priorities on the South China Sea.

Indian Prime Minister Narendra Modi has met China's top diplomat and hailed the “steady progress” made in improving the countries' relationship after a yearslong standoff between the nuclear-armed powers.

Resource constraints and precedent mean China is unlikely to become one of Ukraine's security guarantors - despite Russia's suggestion that it could, according to analysts. With rising expectations for a face-to-face meeting between Russian President Vladimir Putin and his Ukrainian counterpart Volodymyr Zelensky,

China's unabated military construction in Tibet, which is often referred to as the 'water tower of Asia', could trigger a critical water shortage in the future, affecting over 2 billion people across Asia.

Chinese officials have showcased what they claim will be the world's largest solar farm on the Tibetan plateau.

China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen Pharmaceutical for 250 million Chinese yuan ($34.8 million) upfront. | China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen Pharmaceutical for 250 million Chinese yuan ($34.